Why Shares of Evolus Are Jumping Thursday
Shares of (NASDAQ: EOLS) were up more than 25% as of 11 a.m. ET after the company reported record quarterly revenue and increased guidance. The stock is up 31% so far this year.
Evolus is a customer-centric healthcare aesthetics company. Its lead product is Jeuveau, a prescription neurotoxin used to temporarily diminish facial wrinkles in adults. The company reported preliminary second-quarter revenue of $49.3 million, up 33% year over year, and increased its full-year revenue guidance to between $185 million and $195 million, compared to earlier estimates of between $180 million and $190 million.
The company's report was incomplete with full second-quarter results scheduled for Aug. 2. There was no mention of what the company's net income or earnings per share (EPS) was. For example, in the first quarter, Evolus reported an EPS loss of $0.26. Investors will want to see a fuller picture of the company's financials.
Source Fool.com
Evolus Inc Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Evolus Inc, ohne Sell-Einschätzungen.
Das Kursziel von 22 € für Evolus Inc impliziert eine deutliche Steigerung um über 50% gegenüber 13.2 €.
